Latest Communications

19 March 2012
Nautlius Neurosciences, Inc. Announces a New Approval for CAMBIA® in the Acute Treatment of Migraine

01 March 2012
APR Applied Pharma Research ("APR") and Labtec GmbH ("Labtec") announce the European approval of Zolmitriptan Oral Dispersible Film (ODF)

18 January 2012
APR Applied Pharma Research s.a. (“APR”), Labtec GmbH (“Labtec”) and Norgine BV (“Norgine”) announce the signature of an exclusive licensing agreement under which Norgine will market and distribute Setofilm™ Ondansetron Oral Dispersible Film (“ODF”), in Europe and selected non-European countries.


Product Development Plan


All APR products and projects are based on a solid set of scientific data and/or proven technologies but in addition, they are also complemented, supported and maximized by an integrated strategic marketing model.


We define and coordinate the value chain from R&D and technology investments to the final consumer targets in order to deliver competitive products for our healthcare partners as well as effective added value products for patients and consumers.


We focus on strategic product planning: we internally analyze markets, trends and brands in order to identify new product /project opportunities, we identify the best development path for any product/project and we execute and control all the phases in order to deliver to our partners validated products; we finally support our partners and customers during all the launch phases and the commercial lifecycle with an integrated marketing plan.





Search results